From: OncLive <edigest@onclive.com>

Sent: <Day, Month xx, 2020>
To: <<Email Address>>

Subject: Live Broadcast Registration Confirmation: A New Combination for

Advanced Renal Cell Carcinoma

No Images? Click here

#### Dear [Full Name],

This is a reminder that you have registered to view this Live Broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Date: [Month/Day/20]

Time: [XX:XXpm]

### **VIEW LIVE BROADCAST**

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

### Join Our RCC Experts:



Daniel James George, MD

Professor of Medicine and Surgery

Director of GU Oncology

Co-Leader, DCI Center for Prostate & Urologic Cancers

Duke University Medical Center



Ulka Vaishampayan, MD
Professor of Medicine
Division of Hematology/Oncology
University of Michigan



Sumanta Kumar Pal, MD

Clinical Professor

Department of Medical Oncology & Experimental
Therapeutics
City of Hope

## In this Live Broadcast Dr. George, Dr. Vaishampayan, and Dr. Pal will:



Review mechanisms of action of a multitargeted approach to aRCC treatment



**Explore** key efficacy and safety data for a new combination regimen



Provide expert perspectives on clinical trial data



Share clinical insights through a live Q&A

### **VIEW LIVE BROADCAST**






CA-1715 09/20

credit.

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

This program is not certified for Continuing Medical Education





From: OncLive <edigest@onclive.com>

Sent: <Day, Month xx, 2020>

To: <<Email Address>>

Subject: Live Broadcast Registration Confirmation: A New

Combination for Advanced Renal Cell Carcinoma

No Images? Click here

### Dear [Full Name],

This is a reminder that you have registered to view this Live Broadcast to gain an expert perspective on the changing therapeutic landscape and learn about a new combination approach for patients with advanced renal cell carcinoma.

Thank you for your participation!

Date: [Month/Day/20]

Time: [XX:XXpm]

### VIEW LIVE BROADCAST

This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.

Join Our RCC Experts:




Daniel James George, MD Professor of Medicine and Surgery

Director of GU Oncology Co-Leader, DCI Center for Prostate & Urologic Cancers **Duke University Medical Center** 



Professor of Medicine Division of Hematology/Oncology

University of Michigan



#### Department of Medical Oncology & Experimental Therapeutics

City of Hope

In this Live Broadcast Dr. George, Dr.


Vaishampayan, and Dr. Pal will:

# Review mechanisms of action of a



Explore key efficacy and safety data for a new combination regimen

multitargeted approach to aRCC treatment



data

Share clinical insights through a live Q&A

Provide expert perspectives on clinical trial



## VIEW LIVE BROADCAST

OncLive®



CA-1715 09/20

This program is not certified for Continuing Medical Education credit. This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs,

or spouses.

RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests

OncLive® - an MJH Life Sciences™ brand Copyright 2020 © Intellisphere, LLC

2 Clarke Dr I Suite 100 | Cranbury, NJ | 08512

Forward